‹ Insmed
Ch 5 · The Story Behind the Numbers
Chapter 5 · Behind the Numbers
The numbers, in the company's own words.
Every filing has a section where management explains what just happened — and why. Here's Insmed's.
↓ scroll to read
✦ The bottom line
Anyone can read the revenue line. The story — which drug is driving the surge, why the losses are so big, and what's next in the pipeline — is the part Insmed writes itself. Here are the threads that matter.
↓ the brief below
✦ Five threads from Insmed's filings
1
Brinsupri is the inflection.
The new launch of Brinsupri (brensocatib) for bronchiectasis is what tripled revenue year-over-year. Bronchiectasis is a much larger patient population than Arikayce's niche, so this is the drug that can make Insmed substantially bigger.
2
Arikayce is the steady base.
Insmed's first drug, Arikayce, remains a stable, growing revenue stream for a rare lung infection. It funded the company through the years of developing brensocatib and still anchors the top line.
3
The loss is mostly investment.
The $1.25B operating loss is dominated by R&D and the cost of launching a drug nationally. The most recent quarter's loss was far smaller — evidence the revenue ramp is beginning to outrun the spend.
4
There's a pipeline behind the launches.
Insmed is advancing additional programs — including a pulmonary-hypertension candidate and further uses of brensocatib — so the story isn't just two drugs; it's a platform of rare-disease bets at different stages.
5
Funded by the markets, for now.
Like most pre-profit biotechs, Insmed funds its losses by raising capital. The key watch-item is cash runway versus the point where Brinsupri's growth turns the company profitable.
Source · 10-K · MD&A + Business · FY2025 · Filed Feb 19, 2026
●
Read the whole story
Five threads: Brinsupri drives the surge, Arikayce anchors the base, the loss is investment, a real pipeline sits behind it, and capital raises fund the gap.
You just finished
Chapter 5 · BEHIND THE NUMBERS
The Story Behind the Numbers
you now read: reading the MD&A
Up next